TG Therapeutics Profit Margin

The latest profit margin for TGTX is 55.22% as of June 2026. That compares with 13.31% in the prior-year period — up 314.7% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside TG Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TGTX's profit margin moved from 13.31% to 55.22% — a 314.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TG Therapeutics's valuation or profitability profile.

Against Healthcare companies, TGTX currently prints 55.22% for profit margin, while the sector average sits near 9.48%. That is roughly 482.4% above the sector mean. Large gaps often invite a closer look at TG Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively TG Therapeutics converts resources into returns. At 55.22%, TGTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 13.31% in the prior-year period — up 314.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TGTX's profit margin (55.22%), review year-over-year change from 13.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.